Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316695 | 0.84 | MAPT (0.50) | MAPTTDP1 | |
| SCHEMBL4452403 | 0.84 | MAPT (1.00) | MAPTTDP1KMT2AMEN1 | |
| SCHEMBL17625285 | 0.78 | MAPT (0.41) | MAPTTDP1KMT2AKDM4ECDK2 | |
| SCHEMBL9378258 | 0.75 | NOS2 (0.44) | MAPTTDP1KMT2AKDM4E | |
| SCHEMBL26598692 | 0.75 | MAPT (0.39) | MAPTTDP1KMT2AKDM4ECDK2 | |
| SCHEMBL10244272 | 0.74 | MAPT (0.71) | MAPTTDP1 | |
| SCHEMBL14689392 | 0.74 | MAPT (0.42) | MAPTTDP1KMT2AKDM4ECYP2D6 | |
| SCHEMBL17581161 | 0.74 | MAPT (0.38) | MAPTTDP1KMT2AKDM4EHSP90AB1 | |
| SCHEMBL1221544 | 0.74 | NOS2 (0.46) | MAPTTDP1KMT2AKDM4EHSP90AB1 | |
| SCHEMBL28042345 | 0.74 | MAPT (0.38) | MAPTTDP1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066837-A1 | Podophyllotoxin derivatives as antitumor agents | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | US | disclosed |
| EP-1599485-A2 | PODOPHYLLOTOXIN DERIVATIVES AS ANTITUMOR AGENTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004073375-A2 | PODOPHYLLOTOXIN DERIVATIVES AS ANTITUMOR AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-09-02 | — | — | WO | disclosed |
| US-5772990-A | Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated | L'OREAL (FR) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066837-A1 | Podophyllotoxin derivatives as antitumor agents | DIMT1, CYP51A1, MAGT1 | MAPT 4165/4885TDP1 1527/4885KMT2A 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.